INDEMNITY AGREEMENTIndemnity Agreement • July 2nd, 2020 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnity Agreement, dated as of _________ ____, 2020 is made by and between Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), and _____________________, a director, officer or key employee of the Company or one of the Company’s subsidiaries or other service provider who satisfies the definition of Indemnifiable Person set forth below (“Indemnitee”).
NURIX THERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • July 2nd, 2020 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of March 9, 2020, by and among Nurix Therapeutics, Inc., a Delaware corporation (the “Company”) and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
COLLABORATION AND LICENSE AGREEMENT by and between NURIX THERAPEUTICS, INC. and GENZYME CORPORATION dated as of December 19, 2019Collaboration and License Agreement • July 2nd, 2020 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • New York
Each Development Milestone Payment will be payable up to a maximum of one (1) time per Collaboration Target as set forth in the table above, upon achievement of the applicable Development Milestone Event for such Collaboration Target, regardless of the number of times the applicable Development Milestone Event is achieved with respect to such Collaboration Target. For clarity, (x) if for a particular Collaboration Target, the [*], then Sanofi would pay the Development Milestone Payment due under (b) above and milestone (a) in the table above would thereafter not be payable for such Collaboration Target and (y) if for a particular Collaboration Target, the [*], then Sanofi would pay the Development Milestone Payment due under (c) above and milestone (b) in the table above would thereafter not be payable for such Collaboration Target.
ContractCollaboration, Option and License Agreement • July 2nd, 2020 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • California
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
June 15, 2020 Arthur Sands, M.D., Ph.D. Dear Arthur:Letter Agreement • July 2nd, 2020 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This letter (this “Letter Agreement”) sets forth certain basic terms and conditions of a potential option grant to be granted to you by Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), on the terms as set forth below:
